Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Acta Oncologica (Stockholm, Sweden)|August 25, 2005
Prostate cancer cell lines lack amplification: overexpression of HER2Anders Ullén, Lena Lennartsson, Ulrika Harmenberg, et al.
Experimental and Therapeutic Medicine|September 15, 2012
Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancerAsa Jellvert, Ingela Franck Lissbrant, Maliha Edgren, et al.
Acta Oncologica (Stockholm, Sweden)|November 4, 2014
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomesBo Lennernäs, Khairul Majumder, Jan-Erik Damber, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 14, 2010
Effects of IL-2 on MMP expression in freshly isolated human NK cells and the IL-2-independent NK cell line YTKarin Edsparr, Frank M Speetjens, Adri Mulder-Stapel, et al.
Immunology and Cell Biology|May 13, 2009
Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expressionKarin Edsparr, Bengt R Johansson, Ronald H Goldfarb, et al.
The Journal of Urology|July 25, 2017
An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate CancerTeuvo L Tammela, Michael Häggman, Sam Ladjevardi, et al.
Clinical Genitourinary Cancer|October 2, 2012
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesSten Nilsson, Lars Franzén, Christopher Parker, et al.
The Lancet. Oncology|June 5, 2007
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studySten Nilsson, Lars Franzén, Christopher Parker, et al.
International Journal of Oncology|November 16, 2012
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 GyJeff R Cortés-González, Enrique Castellanos, Katinka Sandberg, et al.
Pageof 4